Skip to main content

Market Overview

Collins Stewart: United Therapeutics Reiterates FY12/FY13 Revenue Guidance, Despite 4Q11 Miss

Share:

In a research report published earlier today by Collins Stewart, United Therapeutics (NASDAQ: UTHR) reported 4Q11 total revenues of $195.2M this morning, below Street consensus of $204.8M.

According to Collins Stewart, “4Q11 GAAP EPS was $0.77, also below consensus of $0.87 and CSe of $0.84, with lower revenue and higher stock-based compensation partially offset by lower tax expense. The company reiterated its FY12 revenue guidance of $831M to $919M (vs. consensus of $880.3M and CSe of $896.2M) and its FY13 revenue guidance of $950M to $1.1B (vs. consensus of $982.2M and CSe of $999.8M).”

Collins Stewart maintains its Buy rating and $56 PT on United Therapeutics, which closed yesterday at $49.26.

 

Related Articles (UTHR)

View Comments and Join the Discussion!

Posted-In: Collins StewartAnalyst Color Reiteration Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com